Diagnostic performance of the ClearLLab 10C B cell tube
Autor: | Àngel Bistué-Rovira, Agueda Ancochea, Joan-Ramon Grifols, Sara Vergara, Andrea Espasa, Marc Sorigue, Jorge Bardina, Rosa Linio, Maria-Gloria Soria, Minerva Raya, Jordi Juncà, Silvia Torrents, Cristian Morales-Indiano, Laura G. Rico, Jordi Petriz |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Pathology medicine.medical_specialty Histology Lymphoma Chronic lymphocytic leukemia Antigens CD19 Lymphoproliferative disorders lymphoma CD19 Immunophenotyping Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Antigens CD hemic and lymphatic diseases medicine Humans Lymph node B cell B cells B-Lymphocytes biology business.industry flow cytometry Cell Biology Antigens CD20 Flow Cytometry medicine.disease Leukemia Lymphocytic Chronic B-Cell Lymphoproliferative Disorders Leukemia Lymphoid multiple myeloma 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis biology.protein chronic lymphocytic leukemia Female Neprilysin Bone marrow CD5 ALL lymphoproliferative disorder business |
Zdroj: | CYTOMETRY PART B-CLINICAL CYTOMETRY r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
ISSN: | 1552-4957 1552-4949 |
Popis: | Introduction Pre-analytical and analytical errors can threaten the reliability of flow cytometry (FC) results. A potential solution to some of these is the use of dry, pre-mixed antibodies, such as the ClearLLab 10C system. The purpose of the present study was to compare the diagnostic performance of the ClearLLab 10C B cell tube with that of our standard laboratory practice. Methods We compared the diagnoses made with the ClearLLab 10C B cell tube (experimental strategy) with those made with standard laboratory practice (standard strategy). Samples were selected aiming for representation of the full spectrum of B cell disorders, with an emphasis on mature B cell malignancies, as well as healthy controls. Results We included 116 samples (34 normal controls, 4 acute lymphoblastic leukemias, 54 mature lymphoproliferative disorders in peripheral blood and bone marrow, 3 myelomas, 6 bone marrow samples with involvement by lymphoma and 1 with elevated hematogone count, 14 lymph node samples, 1 cerebrospinal fluid, and 1 pleural effusion). There were two diagnostic errors (1.7%). The agreement between the two strategies in the percentage of CD19 cells and fluorescence intensity of CD5, CD19, CD20, CD200, and CD10 was very good. Conclusions In this study, the ClearLLab 10C B cell tube performed similarly to our standard laboratory practice to diagnose and classify mature B cell malignancies. |
Databáze: | OpenAIRE |
Externí odkaz: |